Trial Profile
An Open-label, Non-randomized, Multicenter Phase I Study to Determine the Maximum Tolerated and / or Recommended Phase II Dose of Oral Mutant IDH1 (mIDH1) Inhibitor BAY1436032 and to Characterize Its Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Efficacy in Patients With mIDH1-R132X Advanced Acute Myeloid Leukemia (AML)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs BAY 1436032 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Bayer
- 01 Nov 2020 Results assessing safety and efficacy of BAY1436032 in IDH1-mutant AML patients published in the Leukemia
- 21 Jun 2020 Results assessing safety and efficacy of mutant IDH1 inhibitor BAY1436032 in advanced AML patients with mutant IDH1 presented at the 25th Congress of the European Haematology Association
- 22 Mar 2019 Status changed from active, no longer recruiting to completed.